On Dec. 17, 2020, ACON Laboratories announced that its SARS-COV-2 IgG/IgM Rapid Test has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.

ACONﾒs SARS-CoV-2 IgG/IgM Rapid Test is a lateral flow chromatographic immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human serum, plasma, and venous whole blood.